PATENT ABSTRACrS

5200336

R E S T R I C T I O N E N D O N U C L E A S E O B T A I N A B L E F O A M B A C I L L U S C O A G U L A N S A N D A P R O C E S S F O R P R O D U C I N G T H E S A M E

Huimin Kong, Ira Schildkraut assigned to New England Biolabs Inc

The present invention provides a novel Type II restriction endonuclease obtainable from Bacil- lus coagulans. The endonuclease known as Bcg I, recognizes the following nucleotide sequence and has a cleavage point at both ends outside of its recognition sequence: See Patent for Chemical Structure PS to produce a 34 base pair fragment. Also described is a process for obtaining purified Bcg I from Bacillus coagulans, as well as pro- cesses for mapping chromosomal DNA and methods for reducing background in trans- formants with enzymes such as Bcg I.

5200337

T Y P E H R E S T R I C T I O N E N D O N U C L E A S E , A P O I,

O B T A I N A B L E F R O M A R T H R O B A C T E R

P R O T O P H O R M I A E A N D A P R O C E S S F O R P R O D U C I N G T H E

S A M E

Carol Polisson, Derek Robinson, Keith Lunnen, Toronto, assigned to New England Biolabs Inc

The present invention provides a novel type II restriction endonuclease obtainable from Ar- throbacter protophormiae. The endonuclease known as Apo I, recognizes the following nucleotide sequence and has a cleavage point in- dicated by the arrows: See Patent for Chemical Structure Also described is a process for ob- taining Apo I from Arthrobacter pro- tophormiae.

5200341

A L T E R E D G E N E A N D E. C O L I S T R A I N S A N D M E T H O D S

U S E F U L I N E N H A N C E D A C C U M U L A T I O N O F P R O T E I N S

Mark Obukowicz assigned to Monsanto Com- pany

An rpoH gene that encodes a sigma32 protein in

129

which cysteine instead of arginine is at amino acid residue 268 was isolated from a mutant of Escherichia coil strain W3110. The rpoH gene has thymine instead of cytosine at the nucleotide position corresponding to 802 in the wild-type rpoH gene. Purified strains ofE. coli W3110 and JMI01 having a mutant rpoH gene in which thymine instead of cytosine is at the nucleotide position corresponding to 802 in a wild-type rpoH gene and a method for synthesis of pro- teins at enhanced levels are also disclosed. The method comprises introducing an expression vehicle into an E. coli strain containing the mutant rpoH gene of this invention.

5200509

H U M A N S O M A T O M E D I N C A R R I E R P R O T E I N S U B U N I T S

A N D P R O C E S S F O R P R O D U C I N G T H E M ; R E C O M B I N A N T D N A

M O L E C U L E S , H O S T S , P R O C E S S E S A N D H U M A N S O M A T O M E D I N C A R R I E R

P R O T E I N - L I K E P O L Y P E P T I D E S

Emerald M Spencer, Carol Talkington-Verser assigned to Celtrix Pharmaceuticals Inc

This invention relates to polypeptides that are human somatomedin carrier protein subunits and to processes for producing them. The carrier protein subunits bind to human somatomedin- like polypeptides also known as insulin-like growth factors. The process involves prepara- tion from a human serum fraction, Cohn IV-l, by a molecule of various chromatographic steps. This invention also relates to DNA molecules encoding human somatomedin carrier protein- like polypeptides, recombinant DNA molecules, hosts, processes for producing carrier protein- like polypeptides, human somatomedin carrier protein-like polypeptides produced using those molecules, hosts and processes. The invention relates to DNA molecules and their expression in appropriate hosts. The recombinant DNA molecules contain DNA molecules that code for polypeptides which have a biological activity of the human carrier protein or a human carrier protein subunit capable of binding somatomedins. The DNA molecules, recom- binant DNA molecules, hosts, and processes of this invention may be used in the production of polypeptides useful in a variety of therapeutic, diagnostic, and other useful applications.